MIT Deshpande Center announces Fall 2012 research grants

December 04, 2012

CAMBRIDGE, Mass. -- The Deshpande Center for Technological Innovation at MIT today announced it is awarding $706,000 in grants to ten MIT research teams currently working on early-stage technologies. These projects have the potential to make a significant impact on our quality of life in cancer treatment, computation, arthritis, recovery from cataract surgery, semiconductor manufacture, image processing, retinal disease detection, food production and distribution.

The Deshpande Center, acting as a catalyst for innovation and entrepreneurship, awards grants that fund proof-of-concept explorations and validation for emerging technologies. "These projects are great examples of the exciting research at MIT. Each of them has the potential to significantly benefit to peoples' lives," says Ian A. Waitz, dean of the School of Engineering. "From healthcare, to big data, to semiconductors, to the food industry -- the Deshpande Center increases the impact of MIT's researchers by accelerating the movement of their work out of the lab and into practical solutions that benefit society."

The fall 2012 grant recipients are:
-end-
The Deshpande Center's mission is to move technologies from the laboratories at MIT to the marketplace. The Deshpande Center grants help recipients assess and reduce the technical and market risks associated with their innovations. In addition to financial support, the Deshpande Center's network of entrepreneurs, venture capitalists, and academic and legal experts helps recipients assess the commercial potential of their innovations and make decisions that accelerate progress toward the development of business plans or licensing strategies.

For more details on the research projects, visit: http://web.mit.edu/deshpandecenter/research_all_grants.html#current

The Deshpande Center has provided $12,000,000 in grants to 100 MIT research projects since 2002. Twenty seven projects have spun out of the center as independent startups, having collectively raised over $400 million in outside financing from investors.

About the MIT Deshpande Center for Technological Innovation

The Deshpande Center is part of the MIT School of Engineering and was established through an initial $20 million gift from Jaishree Deshpande and Desh Deshpande, the co-founder and chairman of Sycamore Networks. It is supported by gifts from alumni, friends and sponsors. The center serves as a catalyst for innovation and entrepreneurship by supporting leading-edge research and bridging the gap between the laboratory and marketplace. Additional information on the Deshpande Center's grant program, research portfolio and other entrepreneurial resources can be found at http://web.mit.edu/deshpandecenter/.

Massachusetts Institute of Technology

Related Arthritis Articles from Brightsurf:

Physical activity and sleep in adults with arthritis
A new study published in Arthritis Care & Research has examined patterns of 24-hour physical activity and sleep among patients with rheumatoid arthritis, lupus, and knee osteoarthritis.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

The ACR and the Arthritis Foundation present new guidelines offering therapeutic approaches and treatment options for juvenile idiopathic arthritis
Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released two guidelines on juvenile idiopathic arthritis (JIA).

Does alcohol consumption have an effect on arthritis?
Several previous studies have demonstrated that moderate alcohol consumption is linked with less severe disease and better quality of life in patients with rheumatoid arthritis, but a new Arthritis Care & Research study suggests that this might not be because drinking alcohol is beneficial.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Which pain medication is safest for arthritis patients?
In a recent Alimentary Pharmacology & Therapeutics study, arthritis patients taking nonsteroidal anti-inflammatory drugs (NSAIDs) for pain plus a stomach acid-reducing medicine called esomeprazole had infrequent gastrointestinal side effects.

Read More: Arthritis News and Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.